Antihypertensive effects of a novel peripheral vasodilator, XXXX .

@entity1 @entity8903 @entity390 @entity101 @entity1296 @entity10
The effects of @entity8903 , a vasodilator, on blood pressure and heart rate, were tested in 13 ambulant @entity1 with mild to severe @entity101 . The @entity1 received @entity8903 in total oral doses ranging from 1.5 to 4 mg/kg over a 3-5 day period. Standard laboratory tests were done 24 h before and after the study. Standing and supine blood pressure and heart rate were determined before, and every hour for 6-8 h after drug administration. ECGs were recorded before, during and at the end of each study day. @entity8903 reduced the pretreatment standing and supine-blood pressure from 213 +/- 34/126 +/- 21 mmHg and 218 +/- 31/130 +/- 20 mmHg to 156 +/- 33/85 +/- 9 mmHg and 158 +/- 25/88 +/- 11 mmHg at the end of Day 5. Heart rate was only transiently increased in @entity1 with pretreatment values of less than 90 beats/min. Although abnormal ECGs tended towards normalization, there were 2 cases of T-wave inversion (the @entity1 remained asymptomatic). Raised BUN levels tended to decrease towards normal. Side effects reported spontaneously by @entity1 ( @entity10 , palpitations, @entity1296 , @entity390 and one case of water retention) appeared to be transient in nature. @entity8903 appeared to be a very potent and long lasting antihypertensive agent, whose inherent side effects were only transient in nature.
